Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study
| Autor: | Ilse Krebs, Birgit Gruenberger, Susanne Binder, Florian Zeiler, Johann Schueller, Katharina E. Schmid-Kubista |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty Visual acuity genetic structures Bevacizumab Eye disease Angiogenesis Inhibitors Antibodies Monoclonal Humanized Cellular and Molecular Neuroscience Macular Degeneration Ophthalmology Medicine Humans Fluorescein Angiography Infusions Intravenous Aged Aged 80 and over medicine.diagnostic_test business.industry Antibodies Monoclonal Macular degeneration medicine.disease Fluorescein angiography Thrombosis eye diseases Sensory Systems Choroidal Neovascularization Surgery Choroidal neovascularization Treatment Outcome Female sense organs medicine.symptom business Epidemiologic Methods Retinopathy medicine.drug |
| Zdroj: | The British journal of ophthalmology. 93(7) |
| ISSN: | 1468-2079 |
| Popis: | Background: Double-blinded, randomised, prospective, pilot-study to determine the effect of systemic bevacizumab therapy. Methods: Subjects with fibrovascular pigment epithelial detachment, subfoveal choroidal neovascularization extending under the geometric centre of the foveal avascular zone, and/or macular thickness of at least 300µm in both eyes were included. Sixteen eyes were included and randomised equally to receive either 3 infusions of 5mg/kg Avastin or 100ml 0.9% sodium chloride every 2 weeks. The main outcome measure was the lesion size. The follow-up time was 24 weeks. Results: Throughout the 24 weeks follow up the lesion size and the macular thickness decreased in the Avastin group by 0.5±0.08mm and 103.6+14.9µl respectively. In both groups visual acuity remained stable in 7 eyes and decreased in 1 eye. At the end of follow up 50% of the eyes in the Avastin group became fibrotic, 37.5% remained unchanged and 12.5% developed a subretinal bleeding. There was an treatable rise in blood pressure after Avastin treatment. Conclusion: We suggest offering systemic Avastin to patients with exudative age-related macular degeneration in both eyes and/or patients who refuse intravitreal injections if blood pressure is normal and there is no history of thrombosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|